Jefferies Cuts STAAR Surgical Target to $155.51 on Estimate Update
0h ago|5 min read1Standard
Fazen Markets Editorial Desk
Collective editorial team · methodology
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. AiX is informational software — not investment advice. Past performance does not guarantee future results.
Jefferies announced a revised price target for STAAR Surgical Company on 13 August 2026, lowering its projection amid an estimate update. The adjustment reflects the investment firm's latest financial modeling for the ophthalmic device manufacturer. STAAR Surgical shares traded at $155.51 as of 21:27 UTC today, registering a 2.11% daily gain. The stock's session range spanned from $154.39 to $156.46 during the trading day.
Price target revisions by major investment banks often signal changing expectations for a company's future earnings potential. Jefferies last adjusted STAAR Surgical's price target on 12 May 2026, when it maintained a $162.00 projection following first-quarter earnings. The current reduction comes during a period of heightened scrutiny for medical device companies facing regulatory headwinds and pricing pressures.
The medical technology sector has experienced mixed performance in 2026, with the iShares U.S. Medical Devices ETF (IHI) showing a 4.2% year-to-date decline through 12 August. Device manufacturers face ongoing challenges from hospital budget constraints and delayed elective procedures. STAAR Surgical specifically has navigated slower adoption rates for its implantable collamer lenses in certain international markets.
Estimate updates typically follow quarterly earnings releases or significant corporate developments that alter revenue projections. STAAR Surgical reported second-quarter earnings on 5 August 2026, missing revenue estimates by 3.1% while exceeding earnings per share expectations. The company's gross margin contracted by 180 basis points year-over-year to 72.4%, primarily due to higher manufacturing costs.
Analyst price target changes often precede institutional positioning adjustments. Jefferies maintains coverage on seventeen medical technology companies, with six receiving rating downgrades since June 2026. The firm's medical device analyst team revised sector earnings estimates downward by an average of 4.7% for the second half of 2026, citing currency headwinds and supply chain inflation.
STAAR Surgical's stock performance shows resilience despite the price target reduction. The shares gained $3.21 during the trading session, reaching $155.51 at the market close. Volume reached 1.24 million shares, 38% above the 30-day average of 898,000 shares. Market capitalization stands at $7.52 billion based on 48.36 million outstanding shares.
The stock's daily trading range of $154.39 to $156.46 represents a 1.3% spread between session high and low. STAAR Surgical shares have declined 12.4% year-to-date, underperforming the S&P 500's 8.7% gain over the same period. The medical devices subsector, as measured by the XHE ETF, has declined 6.9% year-to-date through 13 August.
Jefferies' new $155.51 price target represents a 0.0% implied upside from current levels, suggesting the firm believes the stock is fairly valued. The previous target of $162.00 offered 4.2% potential upside when it was maintained in May. Among sixteen analysts covering STAAR Surgical, the average price target stands at $168.40 with a high of $195.00 and low of $142.00.
The company's valuation metrics show a forward price-to-earnings ratio of 54.3 based on 2027 earnings estimates, compared to the sector median of 28.4. STAAR Surgical trades at 8.2 times sales, above the medical device industry average of 5.3 times sales. The stock's 30-day volatility measures 42.8%, exceeding the S&P 500's volatility of 16.2%.
Short interest stands at 8.9 million shares, representing 18.4% of float and 7.2 days to cover. Institutional ownership totals 87.3% of outstanding shares, with 342 institutions reporting positions. The stock's beta measures 1.38, indicating higher volatility than the broader market over the past year.
The price target reduction reflects concerns about STAAR Surgical's near-term growth prospects amid challenging market conditions. Medical device companies with international exposure face currency headwinds, as the U.S. dollar has strengthened 5.3% against major currencies year-to-date. Companies deriving more than 50% of revenue internationally have underperformed domestic-focused peers by 620 basis points in 2026.
Competitors may benefit from STAAR Surgical's challenges. Alcon Inc. (ALC) gained 1.8% today and has outperformed STAAR Surgical by 14.2% year-to-date. Johnson & Johnson Vision (JNJ) declined 0.3% today but maintains stronger market share in cataract surgery products. Bausch + Lomb Corporation (BLCO) remains neutral with minimal price movement following the news.
One limitation to this analysis is that price target changes don't always immediately impact stock prices, as seen by STAAR Surgical's positive performance today. The market may have already anticipated estimate revisions following the company's recent earnings miss. Some investors view price target adjustments as lagging indicators rather than forward-looking signals.
Institutional flow data shows net selling of $42.3 million in STAAR Surgical shares over the past five trading days. Hedge funds have reduced long positions by 3.7 million shares since the earnings release, while increasing short exposure by 1.9 million shares. Retail investors have been net buyers of $18.2 million in shares during the same period.
STAAR Surgical's next earnings release scheduled for 4 November 2026 will provide crucial data on whether current estimates require further adjustment. The company's third-quarter revenue guidance of $78-82 million represents year-over-year growth of 4-9%, below historical growth rates of 12-15%. Gross margin guidance of 71-73% suggests continued cost pressure.
The American Academy of Ophthalmology annual meeting on 14-17 October 2026 may provide visibility on adoption rates for new products. STAAR Surgical plans to showcase clinical data for its EVO Visian ICL platform, which could influence surgeon adoption decisions. Competitor product launches scheduled for the event may impact competitive dynamics.
Regulatory decisions in key markets will affect future performance. Japan's Pharmaceutical and Medical Devices Agency review of the EVO+ Visian ICL remains ongoing with a decision expected by 31 December 2026. Chinese regulatory approval for the same product is anticipated in first-quarter 2027, representing a potential $50 million annual revenue opportunity.
Technical levels to monitor include support at $150.00, which has held since June 2026, and resistance at $160.00, near the 50-day moving average. A break below $150.00 could trigger further selling toward the 200-day moving average at $142.50. Volume patterns above 1.5 million shares would confirm directional moves.
A price target reduction indicates that analysts believe the stock has less upside potential than previously expected. For STAAR Surgical shareholders, Jefferies' new target suggests the stock is fairly valued at current levels rather than undervalued. Investors should review whether the analyst's concerns align with their investment thesis, particularly regarding growth rates and margin pressures. Price target changes often influence institutional trading decisions more than individual investors' long-term holdings.
Research shows that analyst price target changes correlate with short-term price movements in approximately 65% of cases, with average impact lasting 7-10 trading days. However, the effect varies by analyst reputation, with top-ranked analysts influencing prices more significantly. Price target revisions typically have greater impact when they accompany rating changes rather than standalone estimate updates. Stocks with high institutional ownership show stronger reactions to target adjustments than retail-heavy names.
Analysts revise estimates primarily based on quarterly earnings results, guidance changes, market share shifts, regulatory developments, and macroeconomic factors. For medical device companies like STAAR Surgical, procedure volume trends, reimbursement changes, and competitor product launches frequently trigger estimate updates. Analyst revisions often come in clusters following major company events, with multiple firms updating models within days of each other based on the same information set.
Jefferies' price target reduction reflects calibrated expectations for STAAR Surgical's growth amid sector headwinds.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
AiX is our free MetaTrader 4 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. XAUUSD breakout engine.
Trade 800+ global stocks & ETFs
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
